Ivar Kommers1, Linda Ackermans2, Hilko Ardon3, Wimar A van den Brink4, Wim Bouwknegt5, Rutger K Balvers6, Niels van der Gaag7, Lisette Bosscher8, Alfred Kloet7, Jan Koopmans9, Mark Ter Laan10, Rishi Nandoe Tewarie11, Pierre A Robe12, Olivier van der Veer13, Michiel Wagemakers14, Aeilko H Zwinderman15, Philip C De Witt Hamer16. 1. Department of Neurosurgery, Location VUmc, Cancer Center Amsterdam, Amsterdam University Medical Centers, De Boelelaan 1117, 1081 HV, Amsterdam, Netherlands. 2. Department of Neurosurgery, Maastricht University Medical Center, Maastricht, Netherlands. 3. Department of Neurosurgery, St Elisabeth Hospital, Tilburg, Netherlands. 4. Department of Neurosurgery,, Isala, Zwolle, Netherlands. 5. Department of Neurosurgery, Medical Center Slotervaart, Amsterdam, Netherlands. 6. Department of Neurosurgery, Erasmus University Medical Centre, Rotterdam, Netherlands. 7. Department of Neurosurgery, Medical Center Haaglanden, The Hague, Netherlands. 8. Department of Neurosurgery, Northwest Clinics, Alkmaar, Netherlands. 9. Department of Neurosurgery, Martini Hospital, Groningen, Netherlands. 10. Department of Neurosurgery, Radboud University Medical Center, Nijmegen, Netherlands. 11. Department of Neurosurgery, Leiden University Medical Center, Leiden, Netherlands. 12. Department of Neurology & Neurosurgery, University Medical Center Utrecht, Utrecht, Netherlands. 13. Department of Neurosurgery, Medical Spectrum Twente, Enschede, Netherlands. 14. Department of Neurosurgery, University Medical Center Groningen, Groningen, Netherlands. 15. Department of Clinical Epidemiology and Biostatistics, Amsterdam University Medical Centers, Amsterdam, Netherlands. 16. Department of Neurosurgery, Location VUmc, Cancer Center Amsterdam, Amsterdam University Medical Centers, De Boelelaan 1117, 1081 HV, Amsterdam, Netherlands. p.dewitthamer@amsterdamumc.nl.
Abstract
INTRODUCTION: For decisions on glioblastoma surgery, the risk of complications and decline in performance is decisive. In this study, we determine the rate of complications and performance decline after resections and biopsies in a national quality registry, their risk factors and the risk-standardized variation between institutions. METHODS: Data from all 3288 adults with first-time glioblastoma surgery at 13 hospitals were obtained from a prospective population-based Quality Registry Neuro Surgery in the Netherlands between 2013 and 2017. Patients were stratified by biopsies and resections. Complications were categorized as Clavien-Dindo grades II and higher. Performance decline was considered a deterioration of more than 10 Karnofsky points at 6 weeks. Risk factors were evaluated in multivariable logistic regression analysis. Patient-specific expected and observed complications and performance declines were summarized for institutions and analyzed in funnel plots. RESULTS: For 2271 resections, the overall complication rate was 20 % and 16 % declined in performance. For 1017 biopsies, the overall complication rate was 11 % and 30 % declined in performance. Patient-related characteristics were significant risk factors for complications and performance decline, i.e. higher age, lower baseline Karnofsky, higher ASA classification, and the surgical procedure. Hospital characteristics, i.e. case volume, university affiliation and biopsy percentage, were not. In three institutes the observed complication rate was significantly less than expected. In one institute significantly more performance declines were observed than expected, and in one institute significantly less. CONCLUSIONS: Patient characteristics, but not case volume, were risk factors for complications and performance decline after glioblastoma surgery. After risk-standardization, hospitals varied in complications and performance declines.
INTRODUCTION: For decisions on glioblastoma surgery, the risk of complications and decline in performance is decisive. In this study, we determine the rate of complications and performance decline after resections and biopsies in a national quality registry, their risk factors and the risk-standardized variation between institutions. METHODS: Data from all 3288 adults with first-time glioblastoma surgery at 13 hospitals were obtained from a prospective population-based Quality Registry Neuro Surgery in the Netherlands between 2013 and 2017. Patients were stratified by biopsies and resections. Complications were categorized as Clavien-Dindo grades II and higher. Performance decline was considered a deterioration of more than 10 Karnofsky points at 6 weeks. Risk factors were evaluated in multivariable logistic regression analysis. Patient-specific expected and observed complications and performance declines were summarized for institutions and analyzed in funnel plots. RESULTS: For 2271 resections, the overall complication rate was 20 % and 16 % declined in performance. For 1017 biopsies, the overall complication rate was 11 % and 30 % declined in performance. Patient-related characteristics were significant risk factors for complications and performance decline, i.e. higher age, lower baseline Karnofsky, higher ASA classification, and the surgical procedure. Hospital characteristics, i.e. case volume, university affiliation and biopsy percentage, were not. In three institutes the observed complication rate was significantly less than expected. In one institute significantly more performance declines were observed than expected, and in one institute significantly less. CONCLUSIONS: Patient characteristics, but not case volume, were risk factors for complications and performance decline after glioblastoma surgery. After risk-standardization, hospitals varied in complications and performance declines.
Entities:
Keywords:
Glioblastoma; Karnofsky performance status; Neurosurgical procedures; Patient outcome assessment; Postoperative complications; Quality of health care
Authors: Pierre A Clavien; Jeffrey Barkun; Michelle L de Oliveira; Jean Nicolas Vauthey; Daniel Dindo; Richard D Schulick; Eduardo de Santibañes; Juan Pekolj; Ksenija Slankamenac; Claudio Bassi; Rolf Graf; René Vonlanthen; Robert Padbury; John L Cameron; Masatoshi Makuuchi Journal: Ann Surg Date: 2009-08 Impact factor: 12.969
Authors: Kaisorn L Chaichana; Aditya N Halthore; Scott L Parker; Alessandro Olivi; Jon D Weingart; Henry Brem; Alfredo Quinones-Hinojosa Journal: J Neurosurg Date: 2010-06-04 Impact factor: 5.115
Authors: Susan M Chang; Ian F Parney; Michael McDermott; Fred G Barker; Meic H Schmidt; Wei Huang; Edward R Laws; Kevin O Lillehei; Mark Bernstein; Henry Brem; Andrew E Sloan; Mitchel Berger Journal: J Neurosurg Date: 2003-06 Impact factor: 5.115
Authors: Philip C De Witt Hamer; Vincent K Y Ho; Aeilko H Zwinderman; Linda Ackermans; Hilko Ardon; Sytske Boomstra; Wim Bouwknegt; Wimar A van den Brink; Clemens M Dirven; Niels A van der Gaag; Olivier van der Veer; Albert J S Idema; Alfred Kloet; Jan Koopmans; Mark Ter Laan; Marco J T Verstegen; Michiel Wagemakers; Pierre A J T Robe Journal: J Neurooncol Date: 2019-06-24 Impact factor: 4.130
Authors: Regin Jay Mallari; Michael B Avery; Alex Corlin; Amalia Eisenberg; Terese C Hammond; Neil A Martin; Garni Barkhoudarian; Daniel F Kelly Journal: PLoS One Date: 2021-07-29 Impact factor: 3.240